New research from the University of Toronto suggests a possible link between long-term use of GLP-1 drugs (e.g. Ozempic and Wegovy) and a slightly higher risk of developing wet age-related macular degeneration (AMD). While some previous studies have found no connection or even a protective effect, this new study found that people with type 2 diabetes who were on GLP-1 medications for over 18 months were more likely to develop wet AMD, with the risk increasing the longer they were on the drug.
However, the actual chance of developing the disease remains very low: about 2 out of every 1,000 people taking GLP-1 drugs developed wet AMD, compared to 1 out of every 1,000 who weren–t taking the drugs.
About Fighting Blindness Canada
Fighting Blindness Canada (FBC) is the largest charitable funder of vision research in Canada.
Over our 49-year history, FBC has contributed critical funding for the development of sight-saving treatments and cures for blinding eye diseases. By raising and stewarding funds, FBC is helping drive forward research that supports our goal of understanding why vision loss occurs, how it can be slowed and how sight can be restored.
We are an invaluable resource for individuals and families impacted by blindness, providing accurate eye health information through our website and educational events, as well as engaging with government and other stakeholders to advance better vision health policies.
Want to see more like this article? Click here to subscribe to our FREE print magazines and e- newsletters!
